Compounds and compositions as hedgehog pathway inhibitors

A compound having the structure of Formula I:

• wherein:
• Q1 is selected from an aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, wherein the aryl, heteroaryl, cycloalkyl and heterocycloalkyl of Q1 are optionally substituted with 1 to 3 substituents independently selected from R9, R10, R11, R12 and R13;
• Y1 is N or CR3;
• Y2 is N or CR4;
• Y3 is N or CR2;
• Y4 and Y6 are independently selected from CR8;
• Y5 is CR8;
• Y7 is N or N+O−;
• L1 is selected from a bond, —O—, —O(CR14R14)m—, —(CR14R14)mO—, and —C(O)NR16—;
• L2 is selected from a bond, —(CR14R14)m—, —(CR14R15)m—, —C(O)—, —C(O)(CR14R14)m— and —C(O)(CR14R15)m;
• each L3 is independently selected from a bond, —(CR14R14)m—, —C(O)—, —C(O)O—, and —O(CR14R15)m—;
• R1 is H or C1-C6alkyl;
• R2, R3 and R4 are each independently selected from H, C1-C6alkyl and L3NR16R17;
• each R5 is independently selected from H, CN, halogen, C1-C6alkyl, C1-C6alkoxy, halosubstituted-C1-C6alkoxy, L3OR13, C(O)OR13 and L3NR16R17;
• each R6 is independently selected from H, S(O)R13, SO2R13, SO2NR16R17, L3NR16R17, C(O)OR13, OR13, NR16R17, C(O)NR16R17, C1-C6alkyl, C1-C6haloalkyl, C3-C8cycloalkyl, heteroaryl, heterocycloalkyl,
• a cyclic sulfinyl selected from
• a cyclic sulfonyl selected from
• an aryl and a C1-C6alkyl substituted with 1-4 OH groups,
• wherein the heteroaryl, C3-C8cycloalkyl, cyclic sulfinyl, cyclic sulfonyl and aryl of R6 are optionally substituted with 1-4 substituents selected from halo, CN, C1-C6alkyl, halosubstituted-C1-C6alkyl, C1-C6alkoxy, halosubstituted-C1-C6alkoxy and C1-C6alkyl substituted with 1-4 —OH groups;
• each R7 is independently selected from H and C1-C6alkyl, or n is 1 and R7 is oxo;
• each R8 is independently selected from H and C1-C6alkyl;
• each R9, R10, R11 and R12 are independently selected from H, CN, halo, C1-C6alkyl, halosubstituted-C1-C6alkyl, C1-C6alkoxy, halosubstituted-C1-C6alkoxy, L3OR13, L3NR16R17, L3R13, L3R14, phenyl optionally substituted with 1 to 3 substituents selected from C1-C6alkyl, halo, CN, L3NR16R17 and OR13, and heteroaryl optionally substituted with 1 to 3 substituents selected from C1-C6alkyl, halo, CN, L3NR16R17 and L3OR13;
• alternatively R10 and R11 together with the carbon atoms to which they are attached form a phenyl optionally substituted with 1 to 3 substituents selected from C1-C6alkyl, halo, CN, L3NR16R17 and L3OR13, or R10 and R11 together with the carbons atom to which they are attached form a 5-6 membered heteroaryl optionally substituted with 1 to 3 substituents selected from C1-C6alkyl, halo, CN, L3NR16R17 and L3OR13;
• each R13 is independently selected from H, C1-C6alkyl, C1-C6haloalkyl, C3-C8cycloalkyl, C3-C8heterocycloalkyl, heteroaryl, aryl and a C1-C6alkyl substituted with 1-4 —OH groups, where the heteroaryl and aryl of R13 are optionally substituted with 1 to 3 substituents selected from C1-C6alkyl, C1-C6haloalkyl, C3-C8cycloalkyl, C3-C8heterocycloalkyl, and C1-C6alkyl substituted with 1-4 —OH groups;
• each R14 and R15 are independently selected from H, halo, OH, CN, C1-C6alkyl, C1-C6alkyl substituted with 1-4 —OH groups, halosubstituted-C1-C6alkyl, C1-C6alkoxy and halosubstituted-C1-C6alkoxy;
• or R14 and R15 together with the carbon to which they are attached form a C3-C8cycloalkyl;
• each R16 and R17 are independently selected from H, C1-C6alkyl, and C1-C6alkyl substituted with 1-4 —OH groups;
• each m is independently 1, 2, 3, 4, 5 or 6;
• each n is independently 1, 2, 3, 4, 5 or 6,
• and the pharmaceutically acceptable salts, N-oxides, stereoisomers and diastereoisomers thereof.